Dr Reddy’s Laboratories shares rallied more than 9 percent intraday after Settlement Agreement with US-based Vivus to resolve a long-pending patent litigation related to anti-obesity pill (or weight management capsules) Qsymia.
The settlement agreement permits the company to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of the generic version of Qsymia.
Qysmia is a combination of phentermine and topiramate extended-release sold in capsule form. The drug is used to manage chronic overweight in adults with obesity symptoms.
The drug has gross sales of around USD 73.6 million in 2016.
For more information & more Stocks to buy today.
Call us ✆ – 0731-6642300 or
Visit http://www.epicresearch.co
Connect with our social media sites
YouTube | Google+ |